GVK Bio Says It Found No Link Between Wyeth Prevnar Vaccine And Child Death; Inspectors Did Not Check Documentation
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - GVK Biosciences, the clinical research organization responsible for site monitoring for Wyeth's Prevnar vaccine trial in India has said it found no linkage between the administered vaccine and the death of a child, who died during the course of the clinical trials at Bangalore's St. John's Hospital's National Academy of Health Sciences
You may also be interested in...
Cleared By India's Drug Controller, GVK Bio Expects To Complete Phase III Trials On Wyeth’s Prevnar 13 By Year End
MUMBAI - GVK Biosciences, the clinical research organization undertaking Phase III clinical trials for Wyeth's advanced version of Prevnar vaccine said it hopes to complete the studies in 12 to 13 centers by the end of the year. Wyeth is testing the vaccine in India along with many other countries to examine the new product that will fight 13 strains of bacterial infections instead of the present seven
Cleared By India's Drug Controller, GVK Bio Expects To Complete Phase III Trials On Wyeth’s Prevnar 13 By Year End
MUMBAI - GVK Biosciences, the clinical research organization undertaking Phase III clinical trials for Wyeth's advanced version of Prevnar vaccine said it hopes to complete the studies in 12 to 13 centers by the end of the year. Wyeth is testing the vaccine in India along with many other countries to examine the new product that will fight 13 strains of bacterial infections instead of the present seven
GVK Bio Expects To Complete Phase III Trials On Wyeth’s Prevnar 13 By Year’s End
Wyeth and GVK Biosciences were cleared in May to restart the Indian trials after no links were found between the alleged death of an infant in a Bangalore-based hospital and the trials.